-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $4

Benzinga·03/05/2026 15:04:36
Listen to the news
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $2 to $4.